Biocon Biologics to supply Insulin Aspart drug substance to Civica for US market
Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.
Biocon Biologics, Civica partner to expand Insulin Aspart access in the US
Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration ...
The Financial Express9h
Biocon Biologics partners with Civica to expand Insulin Aspart access in United States
Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...
The Pharma Letter6h
Biocon and Civica link up on Insulin Aspart access in USA
Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a ...
Inquirer on MSN16h
US approves 1st fast-acting insulin biosimilar for diabetes
The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls ...
The Cardiology Advisor2d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
Infectious Disease Advisor6d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
Medscape16d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes.
Monthly Prescribing Reference16d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj ...
Sierra Sun Times17d
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, Mariposa, California and United States ...
Daily Journal20d
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of ...